AR and glioblastoma: However, AR mutations occur in over 30% of GBM cases, limiting the effectiveness AR-targeted therapies [42], 5α-reductase inhibitors can lower systemic dihydrotestosterone levels but may have adverse effects and may not effectively reduce androgen in CSF [43–45].